Methods and compositions for treating melanoma
US-2024424002-A1 · Dec 26, 2024 · US
Mutations in the LNK gene in patients with myeloproliferative neoplasms and other hematolymphoid malignancies
US8945846B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8945846-B2 |
| Application number | US-201113005455-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 12, 2011 |
| Priority date | Jan 14, 2010 |
| Publication date | Feb 3, 2015 |
| Grant date | Feb 3, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Aspects of the present invention include methods, compositions and kits for classifying a subject as having or being predisposed to a hematolymphoid neoplasm or malignancy if they harbor a mutation in the LNK gene. Aspects of the present invention also include screening for candidate agents for treating LNK mutation-based hematolymphoid neoplasms or malignancies in cell-based and cell free assays as well as therapeutic compositions for treating a LNK-mutant based hematolymphoid disorder. Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of identifying a human subject as having or being predisposed to a hematolymphoid neoplasm or malignancy, comprising: (a) obtaining a sample derived from a subject, wherein the sample comprises blood cells and wherein the blood cells do not have a JAK2 V617F mutation; (b) determining the sequence of an LNK gene derived from the sample using PCR or sequencing; and (c) identifying the subject as having or being predisposed to a hematolymphoid neop…
Assignees
Inventors
Classifications
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
- C12Q1/6886Primary
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8945846B2 cover?
- Aspects of the present invention include methods, compositions and kits for classifying a subject as having or being predisposed to a hematolymphoid neoplasm or malignancy if they harbor a mutation in the LNK gene. Aspects of the present invention also include screening for candidate agents for treating LNK mutation-based hematolymphoid neoplasms or malignancies in cell-based and cell free assa…
- Who is the assignee on this patent?
- Gotlib Jason Robert, Nolan Garry P, Zehnder James L, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification C12Q1/6886. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).